Application of CPAG-1 in preparation of ischemic brain injury neuroprotective agent medicine

A technology of ischemic brain injury and CPAG-1, applied in drug delivery, drug combination, medical formula, etc., can solve the problems of inability to receive effective treatment, short time window, lack of treatment, etc., to reduce the volume of cerebral infarction, Reduces neurological deficits and promotes recovery

Active Publication Date: 2022-06-03
XUZHOU MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of stroke mainly includes early thrombolysis and mechanical thrombectomy, but due to the short time window, a large proportion of patients cannot be effectively treated
Up to now, there is still a lack of effective drugs for reducing the volume of cerebral infarction and reducing neurological deficits after stroke, and the development of effective drugs for relieving and treating ischemic brain injury is still a top priority

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CPAG-1 in preparation of ischemic brain injury neuroprotective agent medicine
  • Application of CPAG-1 in preparation of ischemic brain injury neuroprotective agent medicine
  • Application of CPAG-1 in preparation of ischemic brain injury neuroprotective agent medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Statistical effects of CPAG-1 on cerebral infarction volume and cerebral edema.

[0018] The mice in the treatment group (MCAO+CPAG-1) and the control group (MCAO+Vehicle) were scanned by magnetic resonance T2-weighted images after 72 hours of treatment, respectively. The scan results are as follows: figure 1 As shown in the figure, ImageJ was used to calculate the brain dead volume and brain edema size of the MRI T2-weighted image scanning results of the two groups of mice. The statistical results are as follows: figure 2 , image 3 As shown, from the graphical results, the treatment group (MCAO+CPAG-1) can significantly reduce the volume of cerebral infarction and cerebral edema compared with the control group (MCAO+Vehicle).

Embodiment 2

[0019] Example 2: Neurological assessment of mice.

[0020] The mice in the treatment group (MCAO+CPAG-1) and the control group (MCAO+Vehicle) were evaluated for neurological function after 72 hours of treatment, respectively. Right forelimb cannot be fully extended); 2 is moderate neurological deficit (right rotation when walking forward); 3 is severe neurological deficit (body tilts to the right); 4 is very severe neurological deficit (inability to walk spontaneously) , confusion). The evaluation results are as Figure 4 As shown, from the graphical results, the treatment group (MCAO+CPAG-1) can significantly reduce the neurological damage after infarction compared with the control group (MCAO+Vehicle).

Embodiment 3

[0021] Example 3: Evaluation of motor and sensory functions in mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of CPAG-1 in preparation of a neuroprotective agent drug for ischemic brain injury. Belongs to the technical field of brain injury medicines. The CPAG-1 disclosed by the invention is used for preparing a neuroprotective agent medicine for ischemic brain injury to play a brain protection role in ischemic brain injury, specifically, the CPAG-1 can be used for reducing the volume of cerebral infarction and relieving encephaledema after infarction, and meanwhile, the CPAG-1 can be used for remarkably reducing neurological impairment of MCAO mice and promoting the recovery of feeling and movement after stroke.

Description

Technical field: The invention relates to the technical field of brain injury medicines, in particular to the application of CPAG-1 as a preparation of a neuroprotectant medicine for ischemic brain injury. Background technique: Ischemic stroke is an acute cerebrovascular disease that is the third leading cause of death after heart disease and cancer. Due to acute ischemia in the local blood supply area of ​​the brain, infarction and edema of the affected brain area are caused. Survivors after ischemic stroke have a permanent disability rate of up to 80%. Surviving patients often suffer from neurobehavioral deficits such as hemiplegia, slurred speech, incontinence, etc., which seriously affects the survival and quality of life of patients, and causes severe trauma. social and economic burden. [0003] The pathogenesis of ischemic stroke has not been fully elucidated. Stroke causes neuronal death in the brain, increased neuroinflammatory response, release of inflammatory fac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P9/10
CPCA61K45/00A61K9/0019A61P9/10
Inventor 朱太阳周超花放
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap